Chapter 26: Penicillins, Beta-Lactams & Cephalosporins

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

We have a massive task ahead of us today.

We really do.

We are pulling apart chapter 26 of the 12th edition of Pharmacology, a patient -centered nursing process approach.

Honestly, if you are going into nursing or if you just want to understand how modern medicine keeps us from dying of simple scratches,

this is it.

This is the one.

This is the deep dive you save and listen to twice.

It really is.

This chapter is the bedrock.

We're talking about penicillins, other vitilactams, cephalosporins.

The big ones.

They're not just drugs.

They're the primary weapons we have in the war against bacteria.

If you don't understand these, you really can't understand infectious disease treatment.

It is a war.

That's the vibe I got reading this chapter.

It feels like an arms race between human chemistry and bacterial evolution.

That's a perfect way to put it.

But before we get into the heavy artillery, let's set the ground rules.

We are strictly, and I mean strictly, following the source text.

We're going to move from the biology of the enemy, the bacteria itself, through the mechanics of how we kill them, and then deep into the specific drug families.

Which is really the only logical way to do it.

You can't understand why, say, we use a third generation cephalosporin versus a first generation one unless you understand what the bacteria are doing to defend themselves.

This chapter is foundational.

It covers the mechanisms of bacterial destruction, the body's own defenses, the concept of resistance, which is huge, and the specific drug classes that all use that famous beta -lactam ring.

Let's start where the chapter starts with the enemy, pathophysiology.

The text opens by defining bacteria as prokaryotes.

Now for the non -biology majors, or for the students who might have slept through Bio 101,

what does that actually imply for treatment?

It's everything.

It's the fundamental difference that makes the antibiotics even possible.

Prokaryotes are single -celled organisms

that lack a true nucleus and a nuclear membrane.

Human cells, our cells, are eukaryotes.

We have a nucleus.

So that difference is the target?

It's the target.

It gives us something to aim at.

If bacterial cells were exactly like human cells, any drug that killed them would, well, it would kill us too.

Right.

So we need a target that they have and we don't.

And the text immediately highlights the cell wall as the big one.

Exactly.

The cell wall.

Most bacteria have this rigid cell wall.

It determines their shape.

It holds them together against osmotic pressure.

So if you break that wall, the bacteria effectively explodes.

It undergoes lysis.

It just falls apart.

And our cells, human cells, we don't have that kind of rigid wall.

So drugs that target the wall, like penicillins?

Incredibly safe for humans because there's literally nothing in our bodies for them to attack.

It's the perfect weak spot.

The text then breaks down these bacteria by shape.

We see terms like bacillus and coche.

Is this just, you know, trivia for a test or does it actually change how you treat them?

Oh, it's vital.

It's vital for identification.

When you look under a microscope, if you see little rods, those are bacillus.

Rod shaped.

Rod shaped.

If you see little spheres, those are coche.

But it gets even more specific than that.

The text mentions the arrangement.

Right, how they group together.

Yeah.

If those spheres are clustered together like a bunch of grapes, that's staphylococche.

That's your staph infection.

Okay, staph for grapes.

I can remember that.

And if they're in a chain, like a little pearl necklace, that's streptococche.

That's how fast these things replicate.

It's terrifyingly fast.

It's called binary efficient cell division and it happens roughly every 20 minutes.

Every 20 minutes?

Think about that.

You start with one bacterium.

20 minutes later, you have two, then four, then eight.

In just 12 hours, you aren't dealing with a few hundred.

You're dealing with millions.

Wow.

That's why an infection can go from, you know, my throat feels a little scratchy too.

I need to go to the ER in a single day.

The exponential math works against the patient very, very quickly.

So to fight them, we need to know exactly what we're looking at.

The text spends a lot of time on Gram staining.

This feels like really old tech, right?

1882.

It is.

Hans Christian Gramm, a Danish bacteriologist.

It's over a century old, but it is still the gold standard for quick classification.

And it's all about that cell wall structure we just talked about.

All about the wall.

You apply this crystal violet dye.

If the bacteria has a really thick cell wall, a thick peptidylglycan layer, it just soaks up that purple color and holds onto it.

And that's Gram positive?

Correct.

Gram positive equals purple.

The text lists the real heavy hitters here.

Staphylococcus aureus, Streptococcus pneumonia, Clostridium profingens.

If the lab calls you and says, we've got Gram positive Cauchy in clusters, you're already thinking Staph.

So it immediately narrows down your drug choices.

Immediately.

You know what you're dealing with.

And what if it doesn't hold the dye?

Then the dye just washes right out.

And they usually stain them with a counterstain.

So they show up pink or red.

Those are Gram negative.

Like E.

coli.

Right.

Niceremonigetides, E.

coli, hemophilus influenza.

And these are, generally speaking, harder to treat.

Why is that?

Because their cell wall structure is more complex.

They have this outer membrane that acts like an extra layer of armor, an extra shield.

It's just harder for drugs to get in.

Okay.

So we have the shapes and the stain, but the text then introduces the main villain in this story, an enzyme called beta -lactamase.

Yes.

This seems to be the central conflict of the entire chapter.

It is.

This is the bacteria fighting back.

So penicillins and cephalosporins, as we said,

work by attacking the cell wall.

They do this using a very specific chemical structure called a beta -lactam ring.

Okay.

Think of that ring as the key that fits into the lock of the bacterial wall to destroy it.

And the bacteria, over time, learn to break the key.

Precisely.

Some bacteria evolve the ability to produce an enzyme beta -lactamase that literally, chemically, severs that ring.

It snaps it.

And if the ring is broken?

The drug is useless.

It's inert.

It just bounces right off the bacteria.

The bacteria survives, it replicates, and now you have a fully resistant infection.

So when we hear about something like penicillinase, that's just a specific type of this enzyme.

Exactly.

Penicillinase is a beta -lactamase that is specifically designed to destroy penicillin.

This whole concept is why we have so many different antibiotics.

We keep inventing new keys and the bacteria keep changing the locks or inventing new bolt cutters.

It's an incredible arms race.

Okay.

Let's zoom out to the general principles section of the chapter.

The text makes a point of distinguishing between antibiotic, antibacterial, and antimicrobial.

In the hospital, you hear people use these interchangeably all the time, but the text gets a little pedantic about it.

It does, but for good reason.

It's a technical distinction.

An antibiotic, technically, is a chemical produced by one microorganism to kill another.

So like mold -killing bacteria.

Exactly.

It's natural chemical warfare.

Antibacterial and antimicrobial are much broader terms.

They include synthetic drugs made in a lab that inhibit growth or kill microorganisms.

And antimicrobial is the broadest.

It includes viruses, fungi, protozoa.

But in practice.

In practice, if you ask a doctor for an antibiotic, no one's going to correct your terminology.

We all know what we mean.

Speaking of mold, we have to touch on the history here.

The text says 3 ,500 years ago, people were putting moldy bread on wounds.

They had no idea why it worked, but they knew it worked.

It's ancient empiricism, trial and error over centuries.

But the science, the why, that didn't arrive until 1928 with Alexander Fleming.

The most famous accident in medical history.

It really is.

He left the vacation and a mold spore floated in and grew on it.

But he was observant.

He noticed this clear halo around the mold where all the bacteria had died.

And the mold was penicillium notatum.

And it was secreting penicillin.

But look at the timeline in the text.

Fleming discovered it in 1928, but it wasn't mass marketed until 1945.

That's a huge gap.

It took World War II and the need to treat infected wounds on a massive scale to really push the industrialization of it and it changed the world.

Before this, a simple scratch from a rose thorn could genuinely kill you.

So how do these drugs actually kill?

The chapter outlines five specific mechanisms in table 26 .1.

I think it's worth walking through these because killing bacteria is, you know, a bit vague.

We need to be surgical here.

It is.

We have very different ways of sabotaging the cell.

Method one is what we've been talking about.

Inhibition of cell wall synthesis.

The penicillins and cephalosporins.

Right.

They stop the bacteria from repairing or building their walls.

As the bacteria tries to grow, the wall fails and the internal pressure just blows the bacteria apart.

It's bactericidal.

It kills them dead.

Okay.

Simple enough.

Method two.

Alteration of membrane permeability.

This is different from the wall.

This is the the membrane underneath the wall.

Drugs like amphotericin B or polymixins.

They essentially poke holes in that membrane.

And so the cell just leaks out all its vital internal substances, proteins, nucleotides, and it effectively bleeds out at a cellular level.

Method three is inhibition of protein synthesis.

This is a really cool one.

Bacteria have these little protein factories called ribosomes that build everything they need to live.

Okay.

Drugs like tetracyclines or erythromycin.

They basically get in there and gum up the factories.

They jam the machinery.

If the bacteria can't build new proteins, it can't function or grow.

And this is often

Right.

It doesn't always kill them outright.

It stops them from growing, which gives your own immune system time to come in and finish the job.

Got it.

Method four involves RNA and DNA.

Right.

Inhibition of their synthesis.

Fluoroquinolones do this.

They inhibit an enzyme that the bacteria needs to unwind its DNA for replication.

So if you can't read your own blueprints?

You can't replicate.

You can't build anything.

It just shuts down the future of that

colony.

And the last one, method five, is interference with metabolism.

This is what the sulfonamides do.

Bacteria need to make their own folic acid to survive.

We humans, we get folic acid from our food.

Oh, interesting.

So sulfonamides get into that production line for folic acid and block it.

They effectively starve the bacteria of a vital nutrient that it needs to live.

So five completely different ways to attack.

But the text pivots here

pharmacokinetics and pharmacodynamics, because it's not enough to just have the right weapon.

You have to get it to the battle and keep it there.

This is the patient -centered part of the book's title.

It's the practical application.

You have to consider absorption, distribution, excretion.

And the text really highlights half -life.

Which dictates your life as a nurse.

Completely.

If a drug has a short half -life, you are in that patient's room hanging new IV bags every four hours.

If it has a long half -life, maybe it's just a once -a -day pill.

And when do we reach that sweet spot the text calls the steady state?

The magic number is generally four to five half -lives.

That's how long it takes for the drug to build up in the body to a consistent therapeutic level, where the amount you're taking in matches the amount your body is getting rid of.

And it also takes that long to clear it out when you start.

Exactly.

It's a key concept.

There's another term here that's critical.

MEC.

Minimum Effective Concentration.

Think of that as the water line in a flood.

You have to keep the drug concentration above the MEC level to be effective.

To keep the bacteria from growing.

Right.

If you miss a dose, or if the patient has a really fast metabolism, that drug level drops below the MEC.

The moment that happens, the bacteria stop dying and they start recovering.

That's why the timing of administration isn't a suggestion.

It's a non -negotiable requirement.

The text also contrasts continuous infusions with once -daily dosing.

Why would we ever give a drug just once a day if we're so worried about the levels dropping?

It really depends on the drug class.

For some drugs, like aminoglycosides, giving one massive dose once a day is actually safer and more effective.

You hit the bacteria really hard, just overwhelm them.

But then you allow the body, specifically the ears and the kidneys, which are sensitive to these drugs, a long recovery period before the next big hit.

It's a balance between killing the bug and sparing the patient's organs.

Plus, it helps with adherence.

It's easier to remember one pill than four.

Absolutely.

Which brings us to a really humbling point in the chapter.

The drugs don't work alone.

No.

And this is so often overlooked in practice.

Antibiotics are just force multipliers.

They absolutely rely on the host, the patient.

So if your patient is, say, 90 years old, malnourished, with poor circulation and a low white blood cell count, the best antibiotic in the world might fail.

The drug can inhibit the bacteria, it can slow them down, but the patient's own immune system has to do the cleanup.

It has to clear the debris.

So if there's poor circulation to a wound, like in a diabetic patient's foot, then the drug never even arrives at the site of infection.

It's like sending a fire truck to a fire, but the road is completely blocked.

The fire just keeps burning.

This is why things like nutrition and keeping the patient hydrated are actually part of infection control.

Let's talk about the villain's character arc.

Resistance.

The text calls it a crisis and the timeline they present is, frankly,

startling.

It is an evolutionary arms race happening in real time.

The text breaks it down into two types.

First, there's inherent or natural resistance.

Meaning?

Some bacteria just don't have the target the drug hits.

The book's example is Pseudomonas aeruginosa.

It's just naturally resistant to penicillin G.

It just doesn't work.

It never has.

But the real problem is acquired resistance.

That's the one.

This is when a bacteria that used to be sensitive that we could kill easily figures out a way to survive.

And the prime example the book uses is Staph aureus.

The history of Staph is a history of our own hubris.

When penicillin G first came out, Staph was incredibly sensitive to it.

Then, very quickly, it learned to make that enzyme penicillinase.

So we fought back.

We did.

In 1959, we invented methicillin.

Methicillin was specifically designed to resist that enzyme.

We thought, aha,

we've won.

But we didn't.

Not even close.

By 1968, less than 10 years later, we saw the first MRSA, methicillin -resistant Staphylococcus aureus.

And how did it do that?

Stat had evolved again.

It changed the actual binding site that the drug attaches to so the drug couldn't even grab on anymore.

And now MRSA is resistant to all penicillins and cephalosporins.

Pretty much.

So we had to move to a totally different class of drug.

Vancomycin.

That became the heavy hammer for MRSA.

But the story doesn't end there.

No.

Now we have VREF, vancomycin -resistant Enterococcus vasium, and even VRSA, vancomycin -resistant Staph.

We're genuinely running out of walls to breach.

The bacteria are winning the arms race.

The text does list some strategies to combat this.

One is entirely new drug classes like the Oxazolidin runs Linazolid.

Right.

Linazolid is effective against both MRSA and VREF.

But we have to be so careful with it, using it only when absolutely necessary, or the bacteria will figure that out too.

I love the term the text uses here.

Antibiotic resistance disablers.

It's such a smart strategy.

Instead of just trying to invent a stronger antibiotic, you use a smarter combination.

Okay, explain that.

You pair the antibiotic with a suicide molecule that distracts the bacterial enzyme.

We see this

amoxicillin plus clavulinate.

The clavuline basically jumps on the grenade.

It sacrifices itself to the beta -lactamase enzyme.

So that the amoxicillin is free to go kill the bacteria?

Exactly.

It's a brilliant flanking maneuver.

But the text puts a lot of the responsibility for this crisis on the patient and the provider.

It talks about misuse.

They say up to 50 % of hospital antibiotic use is inappropriate.

50%.

That number just seems incredibly high.

It is, but unfortunately reflects reality.

Think about every time someone goes to the doctor for a cold virus and walks out with a prescription for amoxicillin.

Which does nothing for the virus.

Zero good for the virus.

But what it does do is expose all the normal good bacteria in your gut and throat to that antibiotic, and it basically gives them a training session on how to resist it.

And then there's the patient who stops taking the pills after three days because they feel better.

That might be the single most dangerous part of this whole equation.

Explain exactly why that is so dangerous.

Why is day four through ten so important if your symptoms are gone?

Because a bacterial population in an infection isn't uniform.

The first few doses of the antibiotic kill off the weakest, most susceptible bacteria.

That's why you feel better.

The bulk of the bacterial load is gone.

Okay.

But the Spartans,

the strongest, the slightly mucated bacteria, they're still alive.

They're hanging on.

If you stop the drug now, you've just killed off all their competition.

And now they're free to reproduce.

Those Spartans reproduce, and all of their offspring are also Spartans.

You have just personally selectively bred a super infection inside your own body.

That's a chilling way to put it.

The text also mentions cross -resistance and the CNS test.

Cross -resistance means that if a bacteria learns how to beat penicillin,

it probably has a good idea of how to beat a cephalosporin too, because their chemical structures are so similar.

It's like learning to pick a certain type of lock.

Exactly.

Once you know the mechanism, you can open similar doors.

And this is precisely why the CNS, the culture and sensitivity test is so vital.

So explain that process for us.

It's a two -step process.

The culture is where they take a sample, grow the bacteria in a lab, and identify it.

It tells you who is causing the infection.

Okay, that's the C.

Right.

Then the sensitivity, the S, is where they test a bunch of different antibiotics against that specific bacteria to see which ones actually kill it.

It takes all the guesswork out of prescribing.

Okay, moving into therapeutic approaches and adverse reactions.

The chapter discusses combination therapy.

Usually one drug is best, but sometimes we have to mix them.

Right.

And when we mix them, a few things can happen.

One is an additive effect, the sum of the effects, one plus one equals two.

Okay.

The second one is potentative.

That's when one drug enhances the other.

It makes it powerful than it would be on its own.

One plus one equals three.

And the third, the bad one, is antagonistic.

This is what we really want to avoid.

This is where one drug actually blocks or interferes with the other.

The classic example is mixing a bactericidal drug like penicillin with a bacteriostatic drug like tetracycline.

They can actually cancel each other out, and the desired effect is greatly reduced.

We also need to define spectrum, narrow versus broad.

A narrow spectrum antibiotic is very selective.

The book uses erythromycin, which mostly kills gram positives.

You use this when you know exactly what you're fighting.

It's a sniper rifle.

And broad spectrum.

A broad spectrum drug, like tetracycline, hits both gram positive and gram negative bacteria.

Which sounds better, but you've called it a grenade or a nuclear bomb before.

Because it is.

It kills everything, including your body's normal helpful flora, which leads to a lot of other issues.

You often have to use a broad spectrum drug at first, when the patient is very sick, and you haven't identified the organism yet.

But the goal is always to narrow it down as soon as you get those culture results back.

Let's talk about those issues.

Table 26 .2 in the chapter lists the general adverse reactions.

There are three major categories here.

First, and most obvious, is allergy or hypersensitivity.

Which can be a huge range.

A huge range.

From a mild rash or some hives, all the way to severe, life -threatening anaphylaxis laryngeal edema, bronchospasm, cardiovascular collapse.

And the treatment for a severe reaction is immediate.

Epinephrine,

bronchodilators, antihistamines.

Speed is everything.

The second category is super infection.

This is the great irony of antibiotic treatment, right?

The cure causes a new disease.

It is.

We have good bacteria, our normal flora, living in our mouth, our gut, on our skin.

They keep the bad stuff in check.

Broad -spectrum antibiotics kill the enemy, but they also kill all the civilians, the normal flora.

When the good guys are gone, opportunistic pathogens can take over.

And that's when you get things like thrush or C.

diff.

Exactly.

You get fungal infections in the mouth, which is thrush, or clostridioids difficile in the gut, which causes severe, sometimes fatal, diarrhea.

The text notes this is more common with broad -spectrum drugs used for more than a week.

Correct.

And the third major category is organ toxicity.

The liver and the kidneys have to process and filter these drugs.

So we always have to watch for signs of nephrotoxicity, which is kidney damage, and sometimes ototoxicity, which is ear damage.

Okay, that sets the entire stage.

Now let's get into the star of the show, penicillins.

The original beta -lactams, derived from the penicillium mold, as we discussed.

Their whole mechanism is interfering with bacterial cell wall synthesis, using that beta -lactam ring structure.

And the main threat to them is that enzyme we talked about, penicillinase, which is a type of beta -lactame.

Correct.

It breaks the ring and deactivates the drug.

The chapter breaks penicillins down into four distinct types.

Let's walk through them.

First, we have the basic penicillins, G and V.

These are the original, the granddaddies.

Penicillin G is primarily bactericidal, but it has really poor oral absorption.

Stomach acid just chews it up, so it's almost always given by injection, either IV or IM.

And the text makes a point of saying the injection is painful.

Oh, very painful.

It can be like injecting liquid fire.

That's why they often add procaine to the solution.

It's a local anesthetic to decrease the pain, and it also helps extend the drug's activity.

And penicillin V.

That's the oral version.

It's less potent than G, but it's effective for mild to moderate infections.

The text says to take it after meals, although it also notes that doesn't really alter the absorption all that much.

Okay.

Next type, broad -spectrum penicillins, also called amino penicillins.

This is your ampicillin and your amoxicillin.

Amoxicillin is probably the most prescribed penicillin derivative on the planet.

These are effective against gram -positive bacteria and also some gram -negative ones like E.

coli or salmonella.

But there's a big catch.

A huge catch.

They are not penicillinase resistant.

They are readily inactivated by beta -lactamase enzymes.

So they are completely ineffective against most strains of scaphorias today.

Which naturally leads us to the third type, the penicillinase -resistant penicillins, also known as the anti -staphylococcus.

These drugs were designed specifically to fight that enzyme.

The examples in the book are dicloxacillin, which is oral, and then napcillin or oxicillin, which are given IV or IM.

So you use these specifically for staph aureus?

Yes, specifically for penicillinase -producing S.

aureus.

But, and this is important, they are not effective against gram -negatives.

They are very specialized snipers.

Got it.

And the fourth type, the extended -spectrum penicillins, or anti -pseudomonals.

These are the heavy hitters for the really difficult gram -negatives.

The classic example the book gives is papricillin.

They are effective against Pseudomonas aeruginosa, which is a notoriously tough bug to kill, especially in hospitals.

But are they penicillinase -resistant on their own?

No, they are not.

That's a critical distinction.

They have a very broad spectrum of activity, but that beta -lactamase enzyme can still take them out.

So how do we fix that?

This brings us right back to the beta -lactamase inhibitors.

This is that antibiotic resistance disabler strategy we mentioned earlier.

This is the combination therapy.

You combine a powerful, broad -spectrum antibiotic with an inhibitor molecule.

The suicide molecule.

Suicide molecule.

It sacrifices itself to the enzyme so the antibiotic can go do its job.

And the text lists three of these inhibitors, clavulanic acid, solbactam, and tozobactam.

And we see them in some of the most famous drug combinations out there.

Amoxicillin plus clavulanic acid is augmented.

That's the oral one.

What about parenteral, the IV version?

Amposilin plus solbactam is sold as unessin.

And pipercillin plus tozobactam is zoosin.

These combinations just dramatically extend the antimicrobial effect of the parent drug.

Let's touch on the pharmacokinetics of penicillins really quickly.

Okay.

Amoxicillin is generally well absorbed.

Dicloxacillin, on the other hand, is only partially absorbed.

A really key difference is protein binding.

Okay.

Dicloxacillin is highly protein bound.

We're talking 95 to 99 percent.

Amoxicillin is very low, only about 20 percent.

And excretion.

Where do they leave the body?

Mainly through the kidneys.

And this is a vital point for nurses.

You have to monitor BUN and creatinine, especially in older adults.

Or anyone with kidney issues.

If their renal function starts to drop, you have to decrease the dose to avoid toxicity.

Okay.

What about side effects and interactions?

The most common side effects are GI distress, nausea, vomiting, diarrhea.

Taking the drug with food can help alleviate that.

But the big one is always allergy.

It occurs in 5 to 10 percent of patients who take penicillin.

And interactions.

The text lists three very specific ones to watch out for.

Yes.

First, oral contraceptives.

Penicillins may decrease their effectiveness.

That is a huge patient teaching point.

You can't just gloss over that.

Absolutely not.

The instruction has to be clear.

Use a backup method of birth control.

Second, potassium supplements.

If you're taking penicillin G or V, which are potassium salts, you could be at risk for hyperkalemia, high potassium.

Do the third one.

Amino glycosides.

If you mix penicillins and amino glycosides in the same IV solution, they chemically inactivate each other.

You have to run them separately.

Never mix them in the same bag.

Let's try to summarize the nursing process for penicillins.

What are the absolute key takeaways for the nurse at the bedside?

Assessment.

Check for an allergy.

And remember to ask specifically about cephalosporins too because of that cross -sensitivity.

Also, monitor their liver enzymes, ALT and AST,

and definitely their urine output.

And for interventions.

Obtain the culture before starting the first dose of therapy.

I can't stress that enough.

If you give the drug first, you can skew the culture results.

What else?

Monitor closely for superinfection look in their mouth, for white patches, ask about genital discharge or itching, and always have epinephrine available and ready to go in case of anaphylaxis.

And for patient teaching.

Tell them, beg them, to finish the entire bottle to prevent resistance.

If they're chewable tablets, they must be crushed or chewed, not swallowed whole.

And again, advise female patients about the birth control issue and tell anyone with a known allergy to wear a medical alert bracelet.

Very clear.

Now, the text briefly covers the other beta -lactam antibacterial.

Right.

These are sort of the cousins to penicillin.

The examples are asterionam, imipenem, silastatin, and meripenem.

What's special about them?

They're very potent.

Asterionam is interesting because it's limited to aerobic gram negatives, but the carbapenems, that's your imipenem and meripenem, are extremely broad spectrum.

They're some of the biggest guns we have.

But they come with significant risks.

They do.

Adverse reactions include headache, GI distress, and rash.

But the really severe risks are seizures and C, dissociated diarrhea, or CDA.

These are powerful drugs that are often reserved for very serious, complicated infections.

Okay.

Moving to the final major group in the chapter.

The cephalosporins.

I love the origin story the text gives for these.

It is great, isn't it?

Discovered in 1948 in a fungus that was isolated from a sewer outlet off the coast of Sardinia.

From a sewer to a lifesaver.

It's incredible.

It is.

And structurally, they are very similar to penicillin.

They have a beta -lactam structure, and they work the exact same way.

They inhibit cell wall synthesis.

They are back to recital.

But the key to understanding cephalosporins, as the book lays out, is the generations.

There are five of them.

Let's walk through that progression.

Generation one.

Okay, generation one.

Think cephizolin or cephalexin.

These are mostly for gram -positive bacteria, your strep, and your staph.

But, and this is the key, they are easily destroyed by beta -lactamuses.

Okay, so then we need a generation two.

Right.

Like cephaloclar or cephotonin.

With these, you get broader gram -negative coverage, and you start to get some anaerobic coverage as well.

A little more versatile.

Generation three.

This feels like a major turning point in the chapter.

It really is.

The examples are ceftriaxone or ceftanir.

Now, for the first time, we have drugs that are resistant to those beta -lactamuses.

They have a broad spectrum, including activity against pseudomonas.

And crucially, some of them can cross the blood -brain barrier.

And why does that matter so much?

Meningitis.

An infection of the fluid surrounding the brain and spinal cord.

You have to have a drug that can actually get into that fluid to treat it.

Third -gen cephalosporins can do that.

So what's left for generation four?

Cifatema.

This one is highly resistant to beta -lactamuses,

and this is its key feature.

It has excellent penetration into the cerebrospinal fluid, the CSF, that makes it extremely useful for things like meningitis and other severe hospital -acquired infections.

And finally, the newest one, generation five.

Cepteraline.

This is the only generation of cephalosporins that is effective against MRSA.

That is its claim to fame.

It combined to specific mutated protein that MRSA uses to resist all the other beta -lactam drugs.

So as you go from generation one up to five, you're generally getting a broader spectrum and better resistance to those bacterial enzymes.

That's the general trend, yes.

Although you do sometimes trade off some of that potent gram -positive coverage in the middle generations.

It's always a series of trade -offs.

Let's talk pharmacoh for cephalosporins.

They are mostly given IM or IV.

There are only a few oral options, like ceflexin or cefdinir.

For excretion, it's mostly the kidneys.

About 60 to 80 % of the drug is excreted unchanged in the urine.

And what about that allergy cross -sensitivity we mentioned?

This is a classic board exam fact.

Approximately 10 % of people who have a true severe allergy to penicillin will also be allergic to cephalosporins because of that similar beta -lactam structure.

Okay, interactions and side effects.

The text highlights a very specific and serious interaction with alcohol and one of these drugs, cephotinin.

This is critical to know.

It can cause what's called a disulfiram -like reaction.

Flushing, dizziness, severe headache, nausea, vomiting.

It basically mimics the drug that's used to treat alcoholism by making you violently ill if you drink.

So absolutely no happy hour.

Absolutely not.

Patients must be taught to avoid alcohol during treatment, and for at least three days actually they finish the course of cefhotum.

And what about uricocerex, like probenacid?

Probenacid is a gout medication, and it excretes the adrenal excretion of cephalosporins.

That means the drug stays in the body longer and at higher concentrations, increasing its action.

Sometimes that's done intentionally to boost the effect, but it's an interaction you have to watch for.

Okay, last one.

The nursing process for cephalosporins.

Very similar to penicillins.

Assess for allergies to both classes.

Monitor their renal and liver function, BUN, creatinine, AST, ALT, and always, always get the culture before you start therapy.

For IV administration, any special tips?

The book recommends infusing 5 -ecephalosporins over 30 minutes to prevent pain and irritation at the IV site, which is called phlebitis.

And a very practical dietary tip for preventing that superinfusion problem.

The text suggests ingesting buttermilk, yogurt, or an acidophilus supplement.

The idea is to help replace the normal, healthy intestinal flora that the broad spectrum antibiotic is killing off.

That brings us to the end of a very dense chapter.

Let's try to summarize the biggest key takeaways.

Okay.

First, penicillins and cephalosporins are beta -lactam cousins.

They target the bacterial cell wall, which makes them very safe for humans.

Second takeaway.

Resistance is a constant war.

Bacteria evolve enzymes like beta -lactamases to fight back, and we respond by developing enzyme inhibitors in new generations of drugs.

And the third, and maybe most important for the nurse.

Patient safety is everything.

It's about checking allergies, making sure patients finish their entire course of medication,

and constantly monitoring for side effects and super infections.

The text has some review questions that really hammer these points home.

It does.

Like reminding you that a patient with a severe allergy to penicillin should not receive amoxicillin, or that oral contraceptives might fail during antibiotic therapy.

The basics,

but the basics that save lives.

So let's end with our final thought for the listener.

What's the one thing they should be mulling over after this deep dive?

The text ends on a slightly ominous note.

It mentions that new drugs are constantly being developed, but that resistance always follows closely behind.

It implies that this isn't a problem we're ever going to solve.

It's a perpetual race.

And the nurse's vigilance in proper administration, in patient education, that is actually the first line of defense in slowing the bacteria down.

Where are the gatekeepers?

A sobering but very motivating thought.

That wraps up our deep dive into Chapter 26.

Knowledge really is the best antibiotic we have.

A warm thank you from the Last Minute Lecture Team.

We'll see you in the next deep dive.